| Literature DB >> 33328609 |
Niamh Coleman1,2,3, Bingnan Zhang2,3, Lauren A Byers2,3,4, Timothy A Yap5,6,7,8,9,10.
Abstract
The therapeutic landscape of drugs targeting the DNA damage response (DDR) is rapidly expanding; however, an urgent unmet need remains for validated predictive biomarkers of response. SLFN11 has emerged as a promising predictor of sensitivity to DNA-damaging chemotherapies, and recently, been associated with sensitivity to PARP inhibition. We discuss its use as a predictive biomarker of response for targeting the DDR.Entities:
Mesh：
Substances：
Year: 2020 PMID： 33328609 PMCID： PMC7921443 DOI： 10.1038/s41416-020-01202-y
Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640